Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a phase I, single-center, non-randomized, 3+3 dose-escalation study of alpha lipoic
acid given during chemotherapy-radiation in HNSCC patients with non-metastatic disease.